AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 18, 2026, 7:00 AM ET Can-Fite says the last patient in the interim-analysis cohort completed dosing in its pivotal Phase III Piclidenoson psoriasis study; interim results expected Q1 2027. AI-generated summary · Source: SEC filing
NYSE American: $CANFBiotech · A3 adenosine receptor drugsPsoriasis interim cohort fully dosedSeptember warrants exceed shares in issue

CANF Stock Hub: Can-Fite BioPharma News, Namodenoson and Piclidenoson

Can-Fite BioPharma runs two pivotal Phase III programs on a balance sheet of about $7.0 million at June 30, 2026. On November 18 it said all 247 patients in the interim cohort of its psoriasis study of piclidenoson had completed dosing, with the interim analysis expected in the first quarter of 2027; the liver-cancer study of namodenoson may bring its own interim forward. The money comes from serial warrant deals: September’s inducement alone left warrants over about 6.6 million ordinary shares against 6.1 million in issue, on top of older warrants. The central question is whether the data arrive before the dilution does. November 18 release · October resale prospectus.

Last updated: November 18, 2026Financial period: six months ended June 30, 2026 (the company reports semiannually)Currency: U.S. dollars; 1 ADS = 2 ordinary shares
Full research report · PDF
Can-Fite BioPharma Ltd. ($CANF), research updated November 18, 2026
15 pages on the psoriasis and liver-cancer Phase III interims, first-half 2026 accounts, cash runway, the 2026 warrant inducements, the shelf registration, partners and governance. For personal use only: redistribution prohibited.
Get the report (PDF)
Next catalyst
Q1 2027 · psoriasis Phase III interim analysis

The Independent Data Monitoring Committee is expected to read out the pre-specified interim analysis of the pivotal Phase III study of piclidenoson 3 mg twice daily against placebo in moderate-to-severe plaque psoriasis. The co-primary endpoints at Week 16 are PASI 75 and a static Physician’s Global Assessment of 0 or 1. Form 6-K, November 18, 2026.

Completed: on November 18, 2026 the last patient of the 247-patient interim cohort received the final dose. See the dated calendar.

Can-Fite BioPharma CANF daily stock chart
Daily chart $CANF. Interactive chart with bull and bear scenarios on JC Just Charts →

CANF stock at a glance

Chart analysis · JC
Technical chart analysis of $CANF with bull and bear scenarios on JC Just Charts.
Cash and short-term deposits · Jun 30
$7.0M
$2,985K cash and $4,052K of short-term deposits; $8.5M at December 31, 2025. Interim balance sheet.
Net loss · first half 2026
−$4.6M
Research and development $3.5M; general and administrative $1.4M; revenue $0.2M. Statement of operations.
Operating cash burn · first half
$5.3M
Net cash used in operating activities, against $4.75M a year earlier. Operating review.
Ordinary shares in issue · Sep 25, 2026
6,063,093
12,652,889 if the September warrants are exercised. 424B3 prospectus.
September warrant inducement
~$4.0M
Gross proceeds; new warrants for 3,183,476 American Depositary Shares (ADSs) issued in exchange. Release, September 2.
Next pivotal readout
Q1 2027
Psoriasis interim analysis by the Independent Data Monitoring Committee. November 18 release.

Where Can-Fite stands now

Can-Fite BioPharma Ltd., based in Ramat Gan, Israel, develops oral small molecules that act on the A3 adenosine receptor. Its two late-stage drugs are piclidenoson, in a pivotal Phase III study in moderate-to-severe plaque psoriasis, and namodenoson, in a pivotal Phase III study in advanced hepatocellular carcinoma, the most common liver cancer, in patients with Child-Pugh B7 cirrhosis. Namodenoson is also in a Phase IIb study in metabolic dysfunction-associated steatohepatitis (MASH) and has completed a Phase IIa study in pancreatic cancer. The company has no product on the market; its revenue is the amortization of advance payments from licensing partners. Form 20-F for 2025 · operating review, June 30, 2026

On November 18, 2026 Can-Fite reported that the last patient in the interim-analysis cohort of the psoriasis study had received the final dose of study treatment, completing dosing for the first 247 patients. The randomized, double-blind, placebo-controlled study runs under a protocol agreed with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company expects the Independent Data Monitoring Committee to read out the pre-specified interim analysis in the first quarter of 2027, earlier than the second quarter of 2027 given in its annual report in March. Form 6-K, November 18, 2026 · Form 20-F

The company is small. At June 30, 2026 it held $7.0 million of cash, cash equivalents and short-term deposits, reported a first-half net loss of $4.6 million and used $5.3 million in operations. In September a warrant holder exercised warrants for about $4.0 million of gross proceeds, in exchange for new warrants over twice as many ADSs. The company says its resources at the September 8 report date were sufficient for at least the following twelve months, but that it will need significant additional financing. First-half results release · liquidity

The central question. Can-Fite has more clinical maturity than its balance sheet suggests: two randomized pivotal studies with defined endpoints and a first interim in the first quarter of 2027. The risk is the capital structure. Both 2026 financings have been warrant inducements that replaced existing warrants with more, cheaper ones, and the September warrants alone cover more ordinary shares than are in issue. The test is whether the psoriasis interim and the liver-cancer interim arrive, and succeed, before the next round of dilution. Resale prospectus

▲ The constructive case

The psoriasis interim cohort is fully dosed and the readout has moved forward to the first quarter of 2027. Blinded survival in the liver-cancer study is longer than the design assumed, and the company is evaluating an earlier interim. Licensing partners for piclidenoson in Canada, Spain, Switzerland, Austria, China, South Korea and Central Eastern Europe provide a route to market without building a sales force.

▼ The cautious case

Cash covers roughly a year of spending, the September warrants over about 6.6 million ordinary shares overhang 6.1 million in issue, and a $100 million shelf with an at-the-market facility is in place. Pooled blinded survival says nothing about the drug’s effect, the liver interim has no fixed date, and an interim analysis can end in a futility stop as easily as in a positive signal.

Latest Can-Fite BioPharma news

Nov 18, 2026

Can-Fite pivotal Phase III psoriasis study completes dosing; interim analysis expected Q1 2027

Can-Fite BioPharma announced completion of treatment of the first 247 patients in its pivotal Phase III study of Piclidenoson for moderate-to-severe plaque psoriasis. The last patient in the interim-analysis cohort received the final dose, and the Independent Data Monitoring Committee is expected to read out interim results in Q1 2027. The randomized, double-blind, placebo-controlled study follows a protocol agreed with the FDA and EMA, with co-primary endpoints of PASI 75 and sPGA 0 or 1 at Week 16.

Nov 12, 2026

Piclidenoson demonstrates up to 80% improvement in kidney disease marker in Lowe syndrome preclinical study

Can-Fite published research in Signal Transduction and Targeted Therapy showing piclidenoson corrects cellular abnormalities and improves kidney protein reabsorption in Lowe syndrome preclinical models. Researchers screened 1,280 compounds to identify piclidenoson. In a mouse model, five months of treatment reduced urinary levels of a marker of low-molecular-weight proteinuria by 48–80% compared with untreated mice. A Phase II study in 5 adult patients is under review by Italian Health Authorities.

Nov 9, 2026

Can-Fite reports ten-year survival milestone for advanced liver cancer patient

Can-Fite BioPharma announced that a patient with advanced liver cancer who participated in its completed Phase II Namodenoson study has reached ten years of overall survival and remains cancer-free. The patient, whose complete response was previously reported, follows the nine-year survival announced in November 2025. Namodenoson is being evaluated in the ongoing pivotal Phase III study in advanced HCC with Child-Pugh B7 cirrhosis; as announced on September 2, 2026, the Company is evaluating earlier timing for the planned interim analysis.

Nov 6, 2026

Can-Fite to pursue global licensing and partnerships at BIO-Europe 2026

Can-Fite BioPharma will participate in BIO-Europe 2026 in Cologne, Germany, November 9–11, with additional digital partnering sessions on November 17–18. Dr. Sari Fishman, Vice President of Business Development, will represent the company, focusing on licensing, co-development and commercialization partnerships. The company has generated approximately $20 million in upfront and milestone payments from its regional licensing agreements to date.

Nov 2, 2026

Can-Fite announces Eurasian patent allowance supporting Piclidenoson development and commercialization in Lowe syndrome

The Eurasian Patent Office has issued a notification of readiness to grant a patent covering the use of Piclidenoson for diseases associated with OCRL deficiency, including Lowe syndrome and Dent disease 2. The patent application is owned by Fondazione Telethon, Can-Fite's research partner. Under its agreement with Fondazione Telethon, Can-Fite holds the rights to develop, commercialize, and out-license Piclidenoson for Lowe syndrome. The grant remains subject to completion of the required formalities.

Oct 26, 2026

ESMO: final Phase 2a pancreatic cancer data for namodenoson

On October 26, 2026 Can-Fite announced the presentation of final data from its single-center, open-label Phase 2a study of namodenoson (25 mg twice daily) in 20 patients with advanced pancreatic ductal adenocarcinoma at the ESMO Congress 2026: 14 were treated in the third line, three in the second and three in the fourth. As previously announced, the primary safety endpoint was met: five adverse events in three patients were considered related or possibly related to the drug, all grade 1–2, with no grade 3 or higher treatment-related adverse events and no dose modifications, interruptions or discontinuations. In a post hoc exploratory analysis of eight third-line patients who survived beyond two months, median overall survival was 6.28 months and median progression-free survival 2.27 months; one second-line patient reached progression-free survival of 16.39 months and overall survival of 20.7 months at the September 23, 2026 cutoff. The company describes these findings, from a subgroup selected on survival in a study without a randomized comparator, as hypothesis-generating.

CANF stock catalysts: the dated calendar

  • January 2–5, 2026 — 1-for-3,000 reverse split of the ordinary shares on the Tel Aviv Stock Exchange and change of the ADS ratio to one ADS for two ordinary shares. Completed · operating review
  • March 4, 2026 — First warrant inducement: July 2025 warrants over 795,869 ADSs exercised at a reduced price, new warrants over 1,591,738 ADSs issued. Completed · Form 6-K
  • July 6, 2026 — Enrollment of the 247-patient psoriasis interim cohort completed; interim results then guided to the fourth quarter of 2026 or the first quarter of 2027. Completed · release
  • August 17, 2026 — Preclinical data on namodenoson with gemcitabine in pancreatic cancer. Completed · release
  • August 28, 2026 — F-3 shelf registration for up to $100 million, including an at-the-market offering agreement. Effective · Form F-3
  • September 2, 2026 — Blinded overall survival in the liver-cancer Phase III longer than assumed; earlier interim under evaluation. Second warrant inducement for about $4.0 million gross. Completed · survival release · warrant release
  • September 8, 2026 — First-half 2026 results. Completed · release
  • October 9, 2026 — Resale registration of the ADSs underlying the September warrants declared effective. Effective · 424B3
  • October 26, 2026 — Final Phase IIa pancreatic cancer data presented at the European Society for Medical Oncology (ESMO) Congress. Completed · release
  • November 2, 2026 — Eurasian Patent Office notice of allowance for piclidenoson in Lowe syndrome and Dent disease 2. Completed · release
  • November 9, 2026 — A patient from the completed Phase II liver-cancer study reaches ten years of survival. Completed · single patient · release
  • November 12, 2026 — Preclinical Lowe syndrome study published; Phase II protocol under review in Italy. Completed · release
  • November 18, 2026 — Dosing completed in the 247-patient psoriasis interim cohort. Completed · release
  • Q1 2027 — Psoriasis Phase III interim analysis. Expected · company guidance
  • Q2 2027 or earlier — Liver-cancer Phase III interim analysis; the March annual report guided to the second quarter of 2027 and the company is evaluating an earlier date. Pending · no fixed date
  • October 2028 — Expiry of the September 2026 warrants and agent warrants, two years after their resale registration became effective on October 9, 2026. Instrument term · 424B3

The warrant chain of 2025–2026

Can-Fite’s financing in 2026 has followed one pattern. In July 2025 it issued warrants to an investor. On March 4, 2026 that holder exercised warrants over 795,869 ADSs at a reduced price of $5.00 per ADS, against $9.34 originally, and received new warrants over 1,591,738 ADSs at $5.00, plus placement-agent warrants over 55,711 ADSs at $6.25. On September 2 the holder exercised those 1,591,738 at a reduced $2.50 per ADS for about $4.0 million gross, and received new unregistered warrants over 3,183,476 ADSs at $2.50, exercisable for two years from the effective date of their resale registration, plus placement-agent warrants over 111,422 ADSs. Form 6-K, March 5, 2026 · Interim financial statements, Note 6 · 424B3, October 9, 2026

StepWarrants exercised (ADSs)Exercise price per ADSNew warrants issued (ADSs)New exercise price per ADS
March 4, 2026795,869$5.00 (reduced from $9.34)1,591,738, plus 55,711 to the placement agent$5.00; agent warrants $6.25 (125% of the reduced price)
September 2, 20261,591,738$2.50 (reduced from $5.00)3,183,476, plus 111,422 to the placement agent$2.50; agent warrants $3.125 (125% of the reduced price)

Source: the March 5, 2026 Form 6-K, Note 6 to the interim financial statements and the October 9, 2026 prospectus.

Each step doubled the number of ADSs under warrant and lowered or kept the exercise price. The proceeds were real, about $4.0 million each time, but each step also left behind a larger overhang. The October prospectus states that the ordinary shares in issue would rise from 6,063,093 to 12,652,889 if the September warrants and agent warrants were exercised, and that full cash exercise would bring about $8.31 million. The warrant overhang, not the share count alone, is the relevant measure of the capital base. The offering summary

Can-Fite BioPharma deep dive: the full analysis

The chapters below follow one thread: whether Can-Fite’s two pivotal programs can produce interim results that change its financing position before the warrant overhang and the shelf registration do. They cover the scenarios and what would falsify this reading, the A3 adenosine receptor platform, the psoriasis and liver-cancer Phase III studies, the earlier programs in pancreatic cancer, MASH and Lowe syndrome, the first-half accounts, cash and runway, the share count and warrants, partners, patents and governance, and the red flags. The same research is available as a downloadable PDF in the Research Library. The Merlintrader Research Library collects our dated biotech stock research reports.

01 Three scenarios: data against dilution

Bull case — a clean psoriasis interim and an earlier liver-cancer look

In the favorable path, the Independent Data Monitoring Committee reads out the psoriasis interim in the first quarter of 2027 with a result the company can present as supportive on PASI 75 and the static Physician’s Global Assessment at Week 16. The liver-cancer study brings its interim forward, as management said on September 2 it was evaluating, and the comparison of namodenoson against placebo on overall survival favors the drug. A positive psoriasis result would strengthen the existing licensing agreements, whose partners cover Canada, Spain, Switzerland, Austria, China including Hong Kong, Macao and Taiwan, South Korea and Central Eastern Europe, and could support a new partner for the United States or Europe. In that path, warrant exercises at $2.50 per ADS become likely and bring in up to about $8.31 million, which the prospectus calculates for full cash exercise. November 18 release · September 2 survival release · 20-F, licensing

Base case — readouts arrive, but the money runs ahead of them

The more likely path, on the record so far, is that the psoriasis interim arrives on schedule but is not decisive by itself, because an interim analysis is designed to check safety and decide whether to continue, not to prove efficacy. The liver-cancer interim stays without a fixed date. Cash of about $7.0 million at June 30 plus about $4.0 million gross from September covers roughly a year of spending at the first-half rate, so the company returns to the market in 2027, through the at-the-market facility on its shelf, another warrant transaction or a registered offering. Each step adds to a share base that has grown fast: the weighted average share count in the first half of 2026 was 3,711,018 against 1,137,303 a year earlier, after adjusting for the reverse split. Interim financial statements · F-3 shelf

Bear case — a disappointing interim and a financing under pressure

In the unfavorable path, the psoriasis interim shows a weak effect, the committee recommends a change to the study, or the data are hard to interpret. The company would have to finance the liver-cancer study and its overheads from a smaller valuation, with warrants over more ordinary shares than are in issue already outstanding from September alone. An unsuccessful readout would also weaken the case that the licensing partners make for the drug. Can-Fite discloses in its annual report that NYSE American has continued-listing standards and that it could be delisted if it does not satisfy them; it carried out a 1-for-3,000 reverse split in January 2026. 20-F risk factors · operating review

What would falsify this reading

This hub argues that the decisive variable for Can-Fite is the race between its 2027 interim analyses and its need for new capital. Several developments would show that reading to be wrong or incomplete.

  • A non-dilutive deal. A licensing agreement with a meaningful upfront payment for the United States or Europe would change the financing equation. Current partners pay milestones; the first-half revenue of $0.20 million was amortization of past advances. Statement of operations
  • A further delay in the psoriasis interim. The date moved forward, from the second quarter of 2027 in the March annual report to the first quarter of 2027. A slip back would weaken the catalyst argument. 20-F · November 18 release
  • A fixed date for the liver-cancer interim. If Can-Fite sets the interim analysis earlier, as it is evaluating, the liver study becomes a second near-term catalyst rather than a 2027 question mark. September 2 release
  • Warrant exercise without a new inducement. Exercise of the September warrants at $2.50 per ADS without another repricing would show that holders see value in the stock at that level and would add cash without a new instrument.
  • A rise in operating spending beyond the first-half rate. Operating cash use of $5.31 million in the first half was $0.56 million above the prior year, mainly from accelerated spending on both drugs. A higher run rate would shorten the runway faster than this hub assumes. Operating review

02 What Can-Fite does: one receptor, three molecules

Can-Fite BioPharma Ltd. was founded in Israel and is listed on the Tel Aviv Stock Exchange, with American Depositary Shares on NYSE American. Its platform targets the A3 adenosine receptor, which the company says is highly expressed in inflammatory and cancer cells and has low expression in normal cells. It currently develops three small molecules: piclidenoson, namodenoson and CF602, of which piclidenoson is the most advanced. All are taken by mouth. 20-F, business overview

Piclidenoson is in a pivotal Phase III study in moderate-to-severe plaque psoriasis, the study the company calls COMFORT in its annual report. It has also shown activity in preclinical models of Lowe syndrome, a rare genetic disease. Namodenoson is in the pivotal Phase III study LIVERATION in advanced hepatocellular carcinoma with Child-Pugh B7 cirrhosis, a Phase IIb study in MASH, and has completed a Phase IIa study in pancreatic cancer. CF602 has been studied in erectile dysfunction, a field where the annual report lists competitors including Pfizer, Eli Lilly and Bayer. 20-F, pipeline table

The company has a small management team. Motti Farbstein is Chief Executive Officer, Chief Financial Officer and Chief Operating Officer. Pnina Fishman, Ph.D., is Executive Chairperson and Chief Scientific Officer and, according to the annual report, developed much of the technology the company uses; the report names her retention as a key risk. Combining the chief executive and chief financial roles in one person is a governance point worth noting: there is no separate finance chief to sign off on the accounts. 20-F, cover and risk factors · Form 4, June 2026

Revenue comes from licensing. Piclidenoson for psoriasis is licensed to Cipher Pharmaceuticals for Canada, to Gebro Holding for Spain, Switzerland and Austria, to CMS Medical for China including Hong Kong, Macao and Taiwan, to Kyongbo Pharm for South Korea and to Ewopharma for Central Eastern Europe. These partners paid advances that the company recognizes over time; first-half 2026 revenue was $202 thousand, the same as a year earlier. 20-F, licensing · statement of operations

03 The psoriasis Phase III: 247 patients dosed

The pivotal psoriasis study of piclidenoson is randomized, double-blind and placebo-controlled, and is conducted under a protocol agreed with the FDA and the EMA. Patients receive piclidenoson 3 mg or placebo by mouth twice daily. The co-primary efficacy endpoints at Week 16 are the proportion of patients achieving at least a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) and the proportion achieving a static Physician’s Global Assessment of 0 or 1, meaning clear or almost clear skin. Form 6-K, November 18, 2026

The company had already announced the completion of enrollment of the first 247 patients, the cohort for the pre-specified interim analysis. On November 18, 2026 it said the last of these patients had received the final dose. The interim results are to be read out by the Independent Data Monitoring Committee in the first quarter of 2027. The company states that piclidenoson’s development program includes a safety database of more than 1,500 subjects, and argues that an oral drug with a favorable safety profile could suit patients who need long-term treatment. November 18 release

Three points of caution apply. First, an interim analysis by a monitoring committee typically assesses whether a study should continue, be modified or stop; the release does not say what the committee will disclose or what threshold applies. Can-Fite has been here before: it ended its Phase III ACROBAT study in rheumatoid arthritis after the Independent Data Monitoring Committee recommended, in a pre-planned interim analysis, not to continue, and an earlier Phase II/III study in psoriasis did not meet its primary endpoint. Second, the psoriasis market already includes several oral and injectable treatments from large companies, so the commercial value depends on the size of the effect, not only on reaching statistical significance. Third, the timing has changed more than once: the March annual report guided the interim to the second quarter of 2027, the July 6 release to the fourth quarter of 2026 or the first quarter of 2027, and the November release to the first quarter of 2027. That is earlier than the annual report but no longer includes the fourth quarter, so the date depends on assumptions the company keeps updating. 20-F, pipeline status · July 6 release

For CANF stock, this is the event that dominates 2027. The study is the more advanced of the two pivotal programs, and its endpoints are standard ones that regulators use in psoriasis. A result the company can describe as positive would make a partnering discussion for the larger markets more likely; a negative one would leave the liver-cancer study as the main asset.

04 The liver-cancer Phase III: blinded survival and an interim to be set

LIVERATION is a randomized, double-blind, placebo-controlled pivotal study of namodenoson in advanced hepatocellular carcinoma in patients with underlying Child-Pugh B7 cirrhosis, a group with moderately impaired liver function for whom treatment options are limited. Patients are randomized 2:1 to namodenoson or placebo, and overall survival is the primary efficacy endpoint. The annual report describes a study of about 450 patients, designed on the strength of a Phase II study in Child-Pugh B patients that missed its primary endpoint, overall survival in the whole population of 78 patients, but showed longer survival in the largest subgroup, the 56 patients with Child-Pugh B7 cirrhosis. Form 6-K, September 2, 2026 · 20-F, namodenoson Phase II and Phase III

On September 2, 2026 Can-Fite said blinded overall survival across the whole study population appeared longer than the assumptions behind the study design. The company stated explicitly that the observation reflects the pooled, blinded population, including patients on placebo, and that no conclusion on efficacy or on a difference between the arms can be drawn. In light of the longer survival, it said it was evaluating an earlier timing for the planned interim analysis, which would allow an independent comparison of survival between the arms under the statistical analysis plan. Motti Farbstein said the company was encouraged by the observation while noting that the study remains blinded. September 2 release

Longer pooled survival can have several explanations: a drug effect in the treated two-thirds, a healthier enrolled population than expected, better supportive care, or chance. Only the unblinded comparison can separate them. Longer survival in both arms also means fewer deaths per month, which in an event-driven survival study can delay the point at which enough events have accumulated for the analysis. The company’s statement that it is evaluating an earlier interim should therefore be read as an intention, not a date. The annual report of March gave the second quarter of 2027 for this interim. 20-F, pipeline table

Two single-patient reports support the company’s narrative without adding statistical evidence. On November 9, 2026 Can-Fite said a patient from its completed Phase II liver-cancer study, whose complete response it had reported earlier, had reached ten years of overall survival and remained cancer-free. On September 9 it reported a peer-reviewed case report in the Japanese Journal of Gastroenterology and Hepatology of a patient with decompensated cirrhosis in whom ascites resolved on namodenoson and who, after about 28 months of treatment, underwent a liver transplant. Individual cases cannot show that a drug works across a population. November 9 release · September 9 release

05 Pancreatic cancer, MASH and Lowe syndrome

Pancreatic cancer

On October 26, 2026 Can-Fite presented final data from its Phase IIa study of namodenoson in advanced pancreatic ductal adenocarcinoma at the ESMO Congress 2026 in Madrid. The single-center, open-label study enrolled 20 patients who received namodenoson 25 mg twice daily: 14 in the third-line setting, three in the second line and three in the fourth line. The primary safety endpoint was met: five adverse events in three patients were considered related or possibly related to the drug, all Grade 1–2, with no dose changes and no Grade 3 or higher treatment-related events. Form 6-K, October 26, 2026

The efficacy figures are exploratory. In a post hoc analysis of eight third-line patients who survived beyond two months, median overall survival was 6.28 months and median progression-free survival 2.27 months. One second-line patient had progression-free survival of 16.39 months and overall survival exceeding 20.7 months at the September 23, 2026 data cutoff. The company itself says the subgroup was selected on survival, that the study had no randomized comparator, and that the findings are hypothesis-generating. A planned Phase IIb would test namodenoson with gemcitabine and other standard therapy; on August 17 the company reported preclinical data in which the combination with gemcitabine enhanced the anti-cancer effect. ESMO release · August 17 release

MASH

Namodenoson is also in a Phase IIb study in MASH, which the annual report describes as enrolling. The field is crowded: the company lists Madrigal Pharmaceuticals, Novo Nordisk, Roche, GSK, Sagimet Biosciences, Inventiva, Altimmune and Eli Lilly as competitors. The annual report gives no readout date. 20-F, competition

Lowe syndrome

Lowe syndrome is a rare X-linked genetic disorder caused by mutations in the OCRL gene that affects the eyes, brain and kidneys. On November 12, 2026 Can-Fite reported a publication in Signal Transduction and Targeted Therapy, a Nature Portfolio journal, by researchers at the Telethon Institute of Genetics and Medicine (TIGEM) and collaborators. The researchers identified piclidenoson by screening 1,280 compounds; in a humanized mouse model, five months of treatment reduced a urinary marker of low-molecular-weight proteinuria by 48–80% compared with untreated disease-model mice. A Phase II study in five adult patients, open-label and single-center, with six months of twice-daily treatment, has been designed and is under review by Italian health authorities. On November 2 the Eurasian Patent Office issued a notice of readiness to grant a patent for piclidenoson in diseases associated with OCRL deficiency, including Lowe syndrome and Dent disease 2; the application is owned by Fondazione Telethon, and Can-Fite holds development and licensing rights under its agreement with the foundation. November 12 release · November 2 release

These programs broaden the story but do not change the 2027 financing question: they are preclinical or early clinical, and a five-patient study is designed to look for a signal, not to support approval.

06 First-half 2026 accounts

Can-Fite reports semiannually as a foreign private issuer: annual accounts in the Form 20-F and half-year results on Form 6-K. Its latest accounts cover the six months ended June 30, 2026 and were furnished on September 8, 2026. Results release · interim financial statements

U.S. dollars, thousandsH1 2026H1 2025Change
Revenues202202flat
Research and development expenses3,4563,034+13.9%
General and administrative expenses1,4262,066−31.0%
Operating loss4,6804,898smaller
Financial income, net7922higher
Net loss4,6014,876smaller
Net loss per share, basic and diluted (U.S. dollars)1.244.29split-adjusted
Weighted average ordinary shares3,711,0181,137,303split-adjusted

Source: condensed consolidated statements of operations; percentage changes are a Merlintrader calculation. The statement labels the final line “operating loss”; arithmetically it is the net loss after financial income.

Research spending rose, as expected with two pivotal studies enrolling and dosing, while general and administrative costs fell. The loss per share fell sharply, but that reflects the larger share count rather than lower losses: the weighted share base more than tripled between the two half-years. At June 30, 2026 total assets were $8,055 thousand, total shareholders’ equity $4,855 thousand against $5,592 thousand at the end of 2025, and the accumulated deficit $180,790 thousand. Deferred revenues of $974 thousand in long-term liabilities are the unrecognized part of partner advances. Balance sheet

07 Cash and runway

At June 30, 2026 Can-Fite held $2,985 thousand of cash and cash equivalents and $4,052 thousand of short-term deposits, a total of $7.0 million against $8.5 million at the end of 2025. Operating activities used $5.31 million in the first half, up from $4.75 million, which management attributes mainly to accelerated spending on namodenoson and piclidenoson. Investing activities used $1.0 million, reflecting lower maturities of short-term deposits, and financing activities provided $3.77 million from the March warrant inducement. Operating review · cash-flow statement

The September warrant inducement added about $4.0 million gross, before the placement agent’s fees and expenses. A simple Merlintrader calculation: $7.0 million at June 30 plus about $4.0 million gross is about $11.0 million before fees and before third-quarter spending; at the first-half operating rate, annual cash use is about $10.6 million. That points to roughly a year of funding from mid-2026, consistent with the company’s own statement that its resources at the date of the half-year report were sufficient for at least the next twelve months. September 2 warrant release

The company also says plainly that it will require significant additional financing and that financing may not be available on acceptable terms. The interim financial statements say that management’s going-concern evaluation under Accounting Standards Codification (ASC) 205-40 found conditions that raised substantial doubt (a history of losses, operating cash outflow and reliance on additional financing), and that management concluded its plans alleviate that doubt for at least twelve months; those plans include reducing non-essential expenses and deferring and reprioritizing certain research and development programs until financing is obtained. For a company preparing two pivotal interim analyses in 2027, the practical meaning is that new capital will likely be raised before or around the readouts. Liquidity and capital resources · Note 1

08 Share count, warrants and the shelf

On January 2, 2026 Can-Fite carried out a 1-for-3,000 reverse split of its ordinary shares on the Tel Aviv Stock Exchange, and on January 5 the ADS ratio changed from one ADS for 300 ordinary shares to one ADS for two ordinary shares, which for ADS holders had the effect of a one-for-twenty reverse ADS split. On June 4, 2026 shareholders increased the authorized share capital by 16,000,000 shares to 30,000,000. The October 9, 2026 resale prospectus gives 6,063,093 ordinary shares in issue as of September 25, 2026. That is 1,778,000 more than the 4,285,093 at June 30 (Merlintrader calculation), a smaller increase than the 3,183,476 ordinary shares underlying the warrants exercised in September. Operating review · Note 6 · 424B3

At June 30, 2026 warrants were outstanding over 4,228,828 ordinary shares, across issues dating back to January 2023. The largest line was the March 2026 warrants over 3,183,476 ordinary shares, which were exercised in September. In their place the company issued new warrants over 3,183,476 ADSs, equal to 6,366,952 ordinary shares, and agent warrants over 111,422 ADSs, equal to 222,844 ordinary shares. The September warrants and agent warrants together cover 6,589,796 ordinary shares; the prospectus states that full exercise would take the shares in issue from 6,063,093 to 12,652,889. A Merlintrader calculation: 6,589,796 is about 109% of the shares in issue, before the older warrants that remain outstanding. Warrant table · 424B3

InstrumentUnderlyingTermsStatus
September 2026 new warrants3,183,476 ADSs (6,366,952 ordinary shares)$2.50 per ADS; exercisable until two years after the resale registration became effectiveOutstanding; resale registered October 9, 2026
September 2026 placement-agent warrants111,422 ADSs (222,844 ordinary shares)$3.125, 125% of the reduced price; same termOutstanding
Older warrants, January 2023 to March 2026 issuesAbout 1,045,352 ordinary shares (Merlintrader calculation: 7,635,148 warrants outstanding per the prospectus less the 6,589,796 September warrants)Various prices and termsOutstanding at June 30, 2026
Options to executives24,000 options each to Motti Farbstein and Pnina Fishman, June 4, 2026Form 4 code A (grant)Granted

Sources: 424B3 prospectus, interim warrant table and Forms 4. Warrants are instruments with terms, not shares in issue: they add shares only if holders exercise them, and they are exercised mainly when the ADS trades above the exercise price.

The company also has a shelf registration on Form F-3, filed August 28, 2026, for up to $100 million of ordinary shares, ADSs, warrants, subscription rights and units, including a prospectus supplement for an at-the-market offering agreement covering up to $1,065,000 of ADSs at the time of filing. The F-3 states that, because the company’s public float was below $75 million, primary offerings in any 12-month period are limited to one-third of that float (General Instruction I.B.5 of Form F-3), which in Merlintrader’s reading makes the $100 million a ceiling rather than capacity available at once. A second F-3, filed September 25, registers the resale of the warrant ADSs; both registration statements were declared effective. A Form D filed on September 10 records the private placement of the new warrants. F-3, August 28 · F-3, September 25 · Form D

09 Partners, patents and governance

The licensing network is the main non-dilutive asset. Partners for piclidenoson in psoriasis include Cipher in Canada, Gebro in Spain, Switzerland and Austria, CMS in China, Kyongbo Pharm in South Korea and Ewopharma in Central Eastern Europe. These agreements typically include milestone payments and royalties on sales, so their value depends on approval in each territory. None of the partners covers the United States or the larger Western European markets for psoriasis. 20-F, licensing

On patents, the November 2 notice from the Eurasian Patent Office covers the use of piclidenoson in OCRL-deficiency diseases. The underlying application belongs to Fondazione Telethon; Can-Fite’s rights derive from its agreement with the foundation. November 2 release

Insider ownership is small. The annual report lists Pnina Fishman with 6,356 ordinary shares beneficially owned at the March 2026 record date, below 1% of the class. On June 4, 2026 both Motti Farbstein and Pnina Fishman received 24,000 options to purchase ordinary shares, reported on Form 4 with code A, a grant; after the grant Motti Farbstein reported 33,132 options and Pnina Fishman 34,299. No open-market purchases by officers (Form 4 code P) are on file for 2026. 20-F, major shareholders · Form 4, Motti Farbstein · Form 4, Pnina Fishman

As a foreign private issuer, Can-Fite may follow Israeli home-country governance practices instead of some NYSE American requirements, and its articles divide the board into three classes of directors with staggered terms. In January 2026 NYSE American notified the company that its audit committee no longer had three independent members after a director resigned; the annual report filed in March describes a three-member independent audit committee. The annual report also flags the political, economic and security situation in Israel as a risk to operations. 20-F risk factors

10 Red flags and assessment

The clinical side has moved forward in 2026: the psoriasis interim cohort is fully dosed, the interim date moved earlier, the pancreatic study met its safety endpoint, and the Lowe syndrome program gained a publication and a patent allowance. The financial side has moved the other way. Two warrant inducements in six months each doubled the warrants outstanding, the exercise price fell from $9.34 to $2.50 per ADS, and the September warrants alone now exceed the share count. With a $100 million shelf and an at-the-market agreement in place, the tools for further issuance are ready. Note 6 · F-3

The assessment, in one sentence: Can-Fite is a two-readout story in 2027 with about one year of cash, and the capital base is likely to keep growing unless the psoriasis interim, or a partner, changes the terms on which the company raises money. The pooled survival and single-patient reports are encouraging for the company’s narrative but are not evidence of efficacy; the evidence will come from the unblinded interim analyses.

Merlintrader Health Score · $CANF

2.10out of 5
Balance sheet and cash generation · 30%1.5

$7.0 million of cash and short-term deposits at June 30, 2026 plus about $4.0 million gross in September, against first-half operating cash use of $5.31 million; management’s going-concern evaluation found substantial doubt that it concluded its plans alleviate, and the company states it needs significant additional financing.

Catalyst · 30%3.5

Psoriasis Phase III interim cohort fully dosed, readout expected in the first quarter of 2027; the liver-cancer interim may move earlier but has no date. Interim analyses can be inconclusive.

Dilution and capital allocation · 20%1.0

Two warrant inducements in 2026, each doubling the ADSs under warrant at a lower price; September warrants over 6,589,796 ordinary shares against 6,063,093 in issue; a $100 million shelf with an at-the-market agreement.

Liquidity · 10%2.0

ADSs on NYSE American and ordinary shares in Tel Aviv; a 1-for-3,000 reverse split in January 2026, a January 2026 NYSE American notice on audit-committee composition, and continued-listing standards flagged in the annual report.

Execution · 10%2.0

Psoriasis cohort enrolled and dosed and the interim brought forward; pancreatic safety endpoint met. Against that, a very small team with combined chief executive and finance roles, interim timing that has changed more than once, and a record of setbacks: the Phase III ACROBAT study was stopped after an interim analysis, and earlier psoriasis Phase II/III and liver-cancer Phase II studies missed their primary endpoints.

Assessed on November 18, 2026, on the half-year report for the six months ended June 30, 2026 and the filings and releases through November 18. Weighted calculation: 1.5×30% + 3.5×30% + 1.0×20% + 2.0×10% + 2.0×10% = 0.45 + 1.05 + 0.20 + 0.20 + 0.20 = 2.10. The score describes financial and operational robustness over twelve to eighteen months. It is not a rating, a target price or an indication to buy or sell.

Red flags

  • About one year of cash at the first-half spending rate (Merlintrader calculation); the company says it will need significant additional financing.
  • Two warrant inducements in 2026 lowered the exercise price from $9.34 to $2.50 per ADS and doubled the ADSs under warrant each time.
  • The September warrants alone cover 6,589,796 ordinary shares, more than the 6,063,093 in issue.
  • $100 million shelf registration with an at-the-market offering agreement in place.
  • 1-for-3,000 reverse split in January 2026; NYSE American continued-listing standards flagged as a risk.
  • Liver-cancer survival data are pooled and blinded and cannot show a treatment effect; the interim date is not fixed.
  • Pancreatic efficacy figures come from a post hoc subgroup selected on survival, without a comparator.
  • One executive holds the chief executive, chief financial and chief operating roles; insider ownership is below 1%.

CANF Stock FAQ: Can-Fite BioPharma Questions Answered

What is the next catalyst for CANF stock?

The interim analysis of the pivotal Phase III psoriasis study of piclidenoson, which the Independent Data Monitoring Committee is expected to read out in the first quarter of 2027. On November 18, 2026 the company said all 247 patients in the interim cohort had completed dosing. The liver-cancer interim has no fixed date. November 18 release.

What does the psoriasis study measure?

Patients take piclidenoson 3 mg or placebo by mouth twice daily. The co-primary endpoints at Week 16 are the share of patients with at least a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) and the share reaching a static Physician’s Global Assessment of 0 or 1. The protocol was agreed with the FDA and the EMA. Form 6-K.

Does the longer survival in the liver-cancer study mean namodenoson works?

No. The survival Can-Fite reported on September 2, 2026 is for the pooled, blinded population, including placebo patients, and the company says it cannot show a difference between the arms. Only the interim analysis, which the company is evaluating bringing forward, can compare namodenoson with placebo. September 2 release.

How much cash does Can-Fite have?

$7.0 million of cash, cash equivalents and short-term deposits at June 30, 2026, and about $4.0 million gross from the September warrant exercise. First-half operating cash use was $5.31 million. The company believes its resources fund at least twelve months from the September report but will need significant additional financing. Operating review.

How large is the warrant overhang?

The September 2026 warrants and placement-agent warrants cover 6,589,796 ordinary shares. The resale prospectus states that exercise would raise the shares in issue from 6,063,093 to 12,652,889, and full cash exercise would bring about $8.31 million. Older warrants also remain outstanding. 424B3.

How many ordinary shares does one CANF ADS represent?

Two. After the 1-for-3,000 reverse split of January 2, 2026, the ADS ratio changed on January 5, 2026 from one ADS for 300 ordinary shares to one ADS for two ordinary shares. Operating review.

When does Can-Fite report results?

Can-Fite reports semiannually: half-year results on Form 6-K, the latest on September 8, 2026 for the six months ended June 30, 2026, and annual accounts on Form 20-F. As of November 18, 2026 it has not announced the date of its next results. Half-year release.

What is the Lowe syndrome program?

A preclinical program for a rare genetic kidney, eye and brain disorder, run with Fondazione Telethon. A publication in November 2026 reported a 48–80% reduction in a urinary marker in mice after five months of piclidenoson, and a five-patient Phase II study is under review in Italy. November 12 release.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $CANF or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Biotechnology companies carry clinical, regulatory, commercial and financing risk. Interim analyses can stop or continue a trial without proving a drug works, blinded pooled data cannot show a treatment effect, and companies with little revenue fund themselves by selling shares and warrants. This company reported $7.0 million of cash and short-term deposits at June 30, 2026, a first-half net loss of $4.6 million, and issued warrants in September 2026 over more ordinary shares than it had in issue. Its ADSs trade on NYSE American, which has continued-listing standards. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.